Publications by authors named "P Arranz"
Background/objective: Optimal vitamin D levels are required for bone health and proper functionality of the nervous, musculoskeletal and immune systems. The objective of this study was to assess the efficacy and safety profiles of new weekly calcifediol formulations with the potential to improve adherence and outcome.
Methods: A Phase II-III, double-blind, randomized, multicentre trial (EudraCT 2020-001099-14 and NCT04735926).
Article Synopsis
- Bilastine is a non-sedating antihistamine effective for treating allergies, and this study aimed to compare its different formulations (i.v., i.m., and oral) against dexchlorpheniramine and placebo for their antihistamine activity and onset time.
- Conducted on 25 healthy adults, the study demonstrated that all bilastine formulations provided quick relief (15 min for i.v. and i.m., 30 min for oral) and significantly reduced allergic reactions compared to dexchlorpheniramine and placebo.
- The results showed that bilastine formulations were not only more effective but also safe, with no serious adverse events reported, while dexchlorpheniramine was
Background And Objective: Orodispersible tablets (ODT) rapidly dissolve in the oral cavity and can improve patient's convenience. This pharmacokinetic study assessed the bioequivalence of a novel 20 mg ODT formulation of bilastine compared with bilastine 20 mg tablets in healthy volunteers under fasting conditions.
Methods: A phase I, single-center, open-label, two-period, two-sequence crossover randomized clinical trial was conducted.
Multiple whale-watching vessels may operate around cetaceans at any one time, and targeted animals may experience underwater noise effects. We hypothesised that the cumulative noise of two vessels with low source levels (SLs) will elicit lower behavioural disturbance in short-finned pilot whales (Globicephala macrorhynchus) compared to a single vessel with a higher SL. We measured the behaviour of whales during 26 controls (stationary vessel >300 m) and 44 treatments off Tenerife (Canary Islands, Spain).
View Article and Find Full Text PDFBackground: Bilastine is a second-generation antihistamine for the symptomatic treatment of allergic rhinoconjunctivitis (ARC) and urticaria in adults, adolescents, and children. The pharmacokinetics and safety of oral bilastine 10 mg/d in children aged 2 to 5 years were evaluated.
Methods: This was a multicenter, open-label clinical trial in children aged 2 to 5 years with seasonal or perennial ARC or urticaria treated once daily with bilastine 10 mg orodispersible tablets.